Intercept Pharmaceuticals, Inc.

( )
ICPT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc -0.29%75.846.0%$212.45m
VRXValeant Pharmaceuticals International, Inc. -1.83%17.7214.1%$104.27m
CTLTCatalent, Inc. -0.65%87.602.2%$83.69m
JAZZJazz Pharmaceuticals Plc 0.21%126.352.4%$76.78m
BHCBausch Health Cos., Inc. -1.83%17.720.0%$76.42m
TNXPTonix Pharmaceuticals Holding Corp. -3.45%1.120.5%$57.30m
PRGOPerrigo Co. Plc 2.52%51.726.8%$48.00m
GWPHGW Pharmaceuticals Plc 4.19%113.956.2%$47.92m
ICPTIntercept Pharmaceuticals, Inc. 8.37%52.8316.8%$45.49m
ARGXargenx SE -1.10%228.220.0%$42.94m
AMRNAmarin Corp. Plc -0.14%6.991.5%$42.06m
VRNAVerona Pharma Plc 8.56%8.500.0%$41.91m
PCRXPacira Biosciences, Inc. 4.52%60.9910.3%$41.80m
ICLRICON plc 0.13%190.164.3%$41.27m
MYOKMyoKardia, Inc. 1.23%104.671.8%$39.78m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.